Going Concern (new) — Both Lifeward (49.99% equity stake, $13M+ in loans) and Scilex ($19.7M in outstanding notes) disclosed substantial doubt about ability to continue as going concern, creating concentrated credit and equity risk.

NASDAQ: ORMP ORAMED PHARMACEUTICALS INC. 10-K

Oramed exits oral insulin, pivots to healthcare investments amid Iran conflict escalation

Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 27, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ORMP commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 4, 2026 3:16 AM